- Home
- BLIN vs BIAF Comparison
BLIN vs BIAF Comparison
Compare BLIN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- BIAF
- Stock Information
- Founded
- BLIN 2000
- BIAF 2014
- Country
- BLIN United States
- BIAF United States
- Employees
- BLIN N/A
- BIAF N/A
- Industry
- BLIN EDP Services
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BLIN Technology
- BIAF Health Care
- Exchange
- BLIN Nasdaq
- BIAF Nasdaq
- Market Cap
- BLIN 16.0M
- BIAF 12.2M
- IPO Year
- BLIN 2007
- BIAF 2022
- Fundamental
- Price
- BLIN $1.67
- BIAF $0.50
- Analyst Decision
- BLIN Strong Buy
- BIAF Hold
- Analyst Count
- BLIN 1
- BIAF 1
- Target Price
- BLIN $4.62
- BIAF N/A
- AVG Volume (30 Days)
- BLIN 76.9K
- BIAF 28.5M
- Earning Date
- BLIN 05-13-2025
- BIAF 05-14-2025
- Dividend Yield
- BLIN N/A
- BIAF N/A
- EPS Growth
- BLIN N/A
- BIAF N/A
- EPS
- BLIN N/A
- BIAF N/A
- Revenue
- BLIN $15,394,000.00
- BIAF $9,362,022.00
- Revenue This Year
- BLIN $4.89
- BIAF N/A
- Revenue Next Year
- BLIN $10.49
- BIAF $19.99
- P/E Ratio
- BLIN N/A
- BIAF N/A
- Revenue Growth
- BLIN N/A
- BIAF 269.68
- 52 Week Low
- BLIN $0.76
- BIAF $0.24
- 52 Week High
- BLIN $2.80
- BIAF $3.16
- Technical
- Relative Strength Index (RSI)
- BLIN 57.76
- BIAF 48.50
- Support Level
- BLIN $1.46
- BIAF $0.46
- Resistance Level
- BLIN $1.60
- BIAF $0.54
- Average True Range (ATR)
- BLIN 0.11
- BIAF 0.09
- MACD
- BLIN 0.00
- BIAF -0.01
- Stochastic Oscillator
- BLIN 96.67
- BIAF 12.58
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.